Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Jun;103(6):1131-1139.
doi: 10.1097/TP.0000000000002625.

Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies

William S Oetting  1 , Baolin Wu  2 , David P Schladt  3 , Weihua Guan  2 , Jessica van Setten  4 , Brendan J Keating  5 , David Iklé  6 , Rory P Remmel  7 , Casey R Dorr  3   8 , Roslyn B Mannon  9 , Arthur J Matas  10 , Ajay K Israni  3   11   12 , Pamala A Jacobson  1 ; DeKAF Genomics and GEN-03 Investigators
Affiliations
Observational Study

Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies

William S Oetting et al. Transplantation. 2019 Jun.

Abstract

Background: The immunosuppressants tacrolimus and mycophenolate are important components to the success of organ transplantation, but are also associated with adverse effects, such as nephrotoxicity, anemia, leukopenia, and new-onset diabetes after transplantation. In this report, we attempted to identify genetic variants which are associated with these adverse outcomes.

Methods: We performed a genome-wide association study, using a genotyping array tailored specifically for transplantation outcomes containing 722 147 single nucleotide polymorphisms, and 2 cohorts of kidney allograft recipients-a discovery cohort and a confirmation cohort-to identify and then confirm genetic variants associated with immunosuppressant pharmacokinetics and adverse outcomes.

Results: Several genetic variants were found to be associated with tacrolimus trough concentrations. We did not confirm variants associated with the other phenotypes tested although several suggestive variants were identified.

Conclusions: These results show that adverse effects associated with tacrolimus and mycophenolate are complex, and recipient risk is not determined by a few genetic variants with large effects with but most likely are due to many variants, each with small effect sizes, and clinical factors.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

References

    1. Coemans M, Süsal C, Döhler B, et al. Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. Kidney Int. 2018;94(5):964–973. - PubMed
    1. Gaston RS, Fieberg A, Hunsicker L, et al. Late graft failure after kidney transplantation as the consequence of late versus early events. Am J Transplant. 2018;18(5):1158–1167. - PubMed
    1. Almeida CC, Silveira MR, de Araújo VE, et al. Safety of immunosuppressive drugs used as maintenance therapy in kidney transplantation: a systematic review and meta-analysis. Pharmaceuticals (Basel). 2013;6(10):1170–1194. - PMC - PubMed
    1. Sobiak J, Kamińska J, Głyda M, Duda G, Chrzanowska M. Effect of mycophenolate mofetil on hematological side effects incidence in renal transplant recipients. Clin Transplant. 2013;27(4):E4074–E4014. - PubMed
    1. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46(1):13–58. - PubMed

Publication types

MeSH terms